April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 14, 2025

Postpartum Contraceptives Linked to Depression Risk

Researchers study found that initiating hormonal contraceptives postpartum was associated with an increased risk of depression within 12 months after childbirth.

Conexiant

April 11, 2025

FDA Clears Longest Lasting CGM

Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.

Conexiant

April 10, 2025

Study: Pet Ownership Worth $88,000 Annually, Comparable to Marriage

Researchers used instrumental variable analysis to estimate causal effect of pet companionship on wellbeing and found monetary value is comparable to human social interactions.

Conexiant

April 10, 2025

Medical Oddities: Chewing Gum to Fight Flu & Herpes

Gum that fights viruses, tea that tames tumors, and grip strength that beats your DNA—science is getting creative (and tasty) this week.

Conexiant

April 07, 2025

Cannabis for Pain: ACP Issues Best Practices

New guidelines from the American College of Physicians address the limited benefits and potential harms of cannabis and cannabinoids for chronic noncancer pain management.

Conexiant

April 07, 2025

Placebos Show Promise for PMS

The success may be linked to patient expectations and transparent communication.

Conexiant

April 02, 2025

Maternal Depression Affects Child's Eating Patterns

Early maternal depressive symptoms may hinder children's self-regulation and eating behaviors, according to a recent study.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant